What FEMSelect does

FEMSelect is a women-led medical technology company developing minimally invasive solutions for pelvic floor disorders. Originally founded in Israel in 2012 as POP Medical Solutions and renamed FEMSelect in 2019, the company relocated its headquarters to Newark, Delaware in 2025 to align with its largest commercial market. FEMSelect serves urogynecologists, pelvic floor reconstructive surgeons, and women suffering from pelvic organ prolapse (POP) and urinary incontinence, conditions affecting more than half of women over 50 and nearly one in three women, respectively.

The company's core technology is EnPlace, an FDA-cleared (510(k), 2016) and CE-marked (2018) mesh-free, minimally invasive pelvic floor ligament fixation system. EnPlace uses a patented Finger Guide Delivery System and Anchor Inserter to enable precise anchor placement to the sacrospinous ligaments through a small vaginal incision, without deep dissection or mesh implants. The procedure is performed in approximately 30 minutes (vs. 75-120 minutes for traditional surgical approaches) as a same-day outpatient intervention, with clinical data demonstrating a 92% surgical success rate over four years and 6,000+ procedures performed globally as of February 2026. The portfolio has expanded through distribution partnerships to include Elitone and Elitone URGE (FDA-cleared at-home neuromuscular stimulation devices for stress and urge incontinence, serving 30,000 women cumulatively) and biologic implants (VNEW, DermaPure) distributed through ARMS Medical.

FEMSelect monetizes through three revenue streams: (1) direct sales of EnPlace kits to hospitals, ambulatory surgery centers, and physicians, supported by a 3-step physician certification process (online modules, wet lab, case proctoring) and a national Premier, Inc. GPO agreement covering approximately two-thirds of US healthcare providers; (2) direct-to-consumer e-commerce sales of Elitone devices at $36/month subscription or $429 one-time purchase, with Medicare Part B and HSA/FSA eligibility; and (3) distribution of biologic implants via ARMS Medical's network of 200+ surgeons. International expansion is enabled by exclusive distribution partners in Mexico, Chile, Costa Rica, Panama, and Cyprus. The company is backed by New Age Ventures, Triventures, Robin Hood Ventures, RAD BioMed, Nordwand Capital, Avea Ventures, and Terra Verde Comp, having raised over $12.5M in disclosed funding across Series A, Series B, and follow-on rounds.

Name

FEMSelect

Legal name

FEMSelect Ltd.

Website

https://femselect.com

Company type

Private

Founded year

2012

Operating status

Operating

Headcount range

1–10 employees

Short description

FEMSelect is a women's health medical technology company that commercializes EnPlace, an FDA-cleared mesh-free minimally invasive system for pelvic organ prolapse repair, and distributes Elitone at-home neuromuscular stimulation devices for urinary incontinence. The company serves urogynecologists, pelvic floor surgeons, and women with pelvic floor disorders across the US and international markets.

Ownership category

akta.pro rank

Product category

Women's Pelvic Health Medical Devices

NAICS

Surgical and Medical Instrument Manufacturing (339112), Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)

SIC

Surgical & Medical Instruments & Apparatus (3841), Electromedical & Electrotherapeutic Apparatus (3845)

akta.pro primary industry

Open & Minimally Invasive Surgical Instruments (Handheld, Laparoscopic, MIS) (HLAHADAA)

akta.pro secondary industries

Urogynecology & Pelvic Reconstructive Surgery (Female Pelvic Medicine) (HLAKAJAE), Energy-Based Surgical Devices (Electrosurgery, RF, Ultrasonic, Laser) (HLAHADAC)

Keywords

• Pelvic floor repair
• Minimally invasive surgery
• Women's health devices
• Urinary incontinence treatment
• Pelvic organ prolapse

Headquarters

HQ city

Modi'in

HQ country

Israel

HQ region

Middle East

Offices2 records

Markets served

GTM type

B2B and B2C

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Operations, Marketing or Sales, Personnel, Supply Chain

Revenue model

1. EnPlace Medical Device Sales: FEMSelect generates revenue through the sale of its EnPlace surgical system to hospitals, ambulatory surgery centers, and physicians. The procedure takes approximately 30 minutes vs. 75-120 minutes for traditional approaches, making it economically attractive for healthcare providers.
2. Elitone Consumer Device Sales: Elitone and Elitone URGE are sold directly to consumers at $36/month (subscription) or $429 one-time purchase. Products are HSA/FSA eligible with Medicare coverage available through Original Medicare Part B.
3. Biologic Implant Distribution: Through the ARMS Medical distribution agreement, FEMSelect distributes biologic implant portfolio including VNEW precut decellularized dermal allografts and DermaPure products for pelvic reconstruction, complementing the EnPlace system.

Pricing tiers

Go-to-market motion4 records

Distribution channels5 records

Marketing channels7 records

Core offering

FEMSelect develops, manufactures, and distributes medical devices for women's pelvic health. Its core product is the EnPlace system, an FDA-cleared, minimally invasive, mesh-free device for pelvic organ prolapse repair that uses a patented Finger Guide delivery system to anchor sutures to the sacrospinous ligament without deep dissection. The company also distributes Elitone and Elitone URGE, FDA-cleared at-home neuromuscular stimulation devices for stress and urge urinary incontinence, and biologic implants (VNEW, DermaPure) through a partnership with ARMS Medical.

Product overview

FEMSelect is a women-led medical technology company offering a platform of pelvic health solutions. The core product is EnPlace®, an FDA-cleared minimally invasive mesh-free system for pelvic organ prolapse repair, complemented by distributed consumer medical devices (Elitone® and Elitone URGE) for urinary incontinence treatment. Through partnerships with ARMS Medical, the portfolio also includes biologic implants (VNEW® and DermaPure®) for pelvic reconstruction. The EnPlace system consists of an Anchor Inserter and patented Finger Guide delivery system, while Elitone products are external neuromuscular stimulation devices used at home. This diversified platform addresses pelvic organ prolapse, stress urinary incontinence, urge incontinence, and pelvic reconstruction needs.

Differentiator

Problem solved

Functional benefit

Brands

• EnPlace: FDA-cleared minimally invasive mesh-free system for pelvic organ prolapse repair
• Elitone
• Elitone URGE

Products and services

• EnPlace FDA-cleared, minimally invasive, mesh-free system for pelvic organ prolapse repair. Uses the patented Finger Guide Delivery System to enable anchor placement through the vaginal wall and secure sutures to the sacrospinous ligament without deep dissection or mesh implants. Designed for same-day outpatient procedures for urogynecologists and pelvic floor reconstructive surgeons.
• Elitone FDA-cleared external medical device for at-home treatment of stress urinary incontinence. Uses neuromuscular electrical stimulation through gel pads applied to the perineal area to tone pelvic floor muscles, worn 20 minutes daily for 6 weeks. Sold directly to consumers via femselect.com for $36/month subscription or $429 one-time purchase, with HSA/FSA eligibility and Original Medicare Part B coverage.
• Elitone URGE FDA-cleared external medical device for at-home treatment of urge urinary incontinence and overactive bladder. Uses calming neuromuscular electrical stimulation to reduce sudden urges to urinate, applied 20 minutes daily for 6 weeks. FDA-cleared for over-the-counter use without prescription, sold direct-to-consumer at the same pricing as Elitone.
• VNEW Precut decellularized dermal allograft for pelvic reconstruction procedures. Distributed by FEMSelect through the ARMS Medical partnership to complement the EnPlace surgical system.
• DermaPure Dermal allograft product for pelvic reconstruction procedures. Distributed by FEMSelect through the ARMS Medical partnership to complement the EnPlace surgical system.

Quantifiable outcome

• 6,000+ procedures performed globally
• +6 more outcomes

Named customers7 records

Segments4 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Four partnerships are on record, tiered minor and core.

• medikanaminorChannel Partner/ Reseller/ Distributor · 1 January 2026Market research and distributor identification partner supporting FEMSelect's Latin America expansion. medikana helped identify exclusive distribution partners in key markets including Mexico, Chile, Costa Rica, and Panama.
• ARMS MedicalcoreChannel Partner/ Reseller/ Distributor · 16 December 2025Strategic distribution agreement for biologic implant portfolio including VNEW precut decellularized dermal allografts and DermaPure products for pelvic reconstruction. ARMS Medical brings experience treating over 10,000 patients and engaging 200 surgeons nationwide. The partnership complements EnPlace and represents FEMSelect's capital-efficient strategy to build a diversified platform.
• ElidahcoreChannel Partner/ Reseller/ Distributor · 22 September 2025Strategic partnership to distribute Elitone and Elitone URGE, FDA-cleared at-home devices for urinary incontinence treatment. This partnership expands FEMSelect's portfolio from EnPlace (surgical prolapse repair) into the incontinence market, addressing a condition affecting nearly one in three women. The agreement supports FEMSelect's growth strategy to build a comprehensive platform of women's health solutions.
• Premier, Inc.coreChannel Partner/ Reseller/ Distributor · 1 July 2025National group purchasing agreement providing FEMSelect access to Premier's network of healthcare providers. Premier serves approximately two-thirds of all healthcare providers in the United States, enabling broader adoption of EnPlace as a minimally invasive treatment option.

Scale indicators14 records

Recent moves8 records

Expansion highlights7 records

Direct peers

• Axonics Modulation Technologies: Axonics acquired Bulkamid (hydrogel urethral bulking for SUI) from Contura in 2021 for $200M. Directly comparable: Bulkamid and EnPlace both target the same urogynecology/female pelvic medicine surgeon base for stress urinary incontinence and apical prolapse, with the same physician training and GPO distribution model. FEMSelect board member Rakesh Tailor led the Bulkamid-to-Axonics exit, making this the closest comparable.
• Caldera Medical: Private women's health medtech company focused exclusively on pelvic floor disorders, offering Desara and Vertessa sling systems for stress urinary incontinence and Desara Pro for pelvic organ prolapse. Highly comparable as a similarly-sized specialty player competing in the same FPMRS surgeon channel with single-incision pelvic floor fixation devices.
• InControl Medical: Maker of Apex and Attain at-home neuromuscular stimulation devices for stress and urge incontinence, FDA-cleared for OTC use. Directly competes with FEMSelect's distributed Elitone and Elitone URGE products in the same direct-to-consumer channel at comparable price points, addressing the same female urinary incontinence patient population.

Broad incumbents

• Coloplast: Global medtech incumbent with a dedicated Pelvic Floor Health franchise offering Restorelle mesh, Altis single-incision sling, and surgical continence products. FEMSelect's CCO Joel Chechik previously led sales at Coloplast, and the companies target the same FPMRS surgeon base with overlapping pelvic floor fixation and incontinence offerings, though Coloplast operates at vastly greater scale across multiple product lines.
• Boston Scientific: Major medtech incumbent with a Pelvic Health segment offering mid-urethral slings, mesh products, and the Xenform biologic matrix for pelvic reconstruction. Comparable because it competes with both EnPlace (surgical POP repair) and FEMSelect's ARMS Medical biologic implants (VNEW/DermaPure) for hospital budget and physician mindshare.
• Ethicon (Johnson & Johnson MedTech): J&J's surgical device arm and the historical leader in women's pelvic floor surgery, with the Gynecare TVT sling and Prolift mesh product families. Renee Selman (FEMSelect's Executive Chairwoman) was former Worldwide President of Ethicon Women's Health and Urology. Comparable as the dominant incumbent that EnPlace is positioned to displace for mesh-averse surgeons.
• CooperSurgical: Women's health-focused subsidiary of CooperCompanies providing a broad portfolio including the Frigg, Restora, and Sundance sling systems for pelvic floor disorders. Comparable as a diversified women's health platform serving the same urogynecology specialist base, though CooperSurgical spans fertility, obstetrics, and surgical solutions beyond pelvic floor.

Emerging players

• Atlantic Therapeutics: Developer of the INNOVO non-invasive pelvic floor stimulation device for stress urinary incontinence, sold primarily via direct-to-consumer channels in Europe and the US. Comparable as a non-surgical, at-home electrical stimulation alternative competing with Elitone for the same conservative-treatment patient segment.
• Renovia: Boston-based women's health startup developing the leva Pelvic Health System, an FDA-cleared digital pelvic floor training device for stress urinary incontinence. Comparable as a venture-backed, single-focus women's pelvic health company with both a connected device offering and physician-channel distribution competing for similar patient and provider mindshare.

Regional players

• Neomedic International: Spain-based medical device company specializing in pelvic floor reconstruction products including the Contasure and Needleless single-incision sling systems. Comparable as a specialty competitor offering minimally invasive mesh and sling alternatives for POP and SUI, primarily serving European and Latin American markets where FEMSelect is now expanding via distribution partners.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/FEMSelect
• Facebookfacebook.com/FEMSelect

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles14 records

Funding overview

Funding rounds7 records

Investors14 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about FEMSelect